scholarly journals Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: A potential biomarker identified by proteomics

2011 ◽  
Author(s):  
Jiri Petrak
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cancer Patients ◽  
Binding Protein ◽  
Retinol Binding Protein ◽  
Retinol Binding Protein 4 ◽  
Potential Biomarker

Retinol‐binding protein 4 (RBP4), a potential biomarker of frailty in HIV‐infected people on stable antiretroviral therapy

HIV Medicine ◽  
2019 ◽  
Vol 21 (6) ◽  
pp. 358-364
Author(s):  
J‐R Blanco ◽  
L Romero ◽  
E Ramalle‐Gómara ◽  
L Metola ◽  
V Ibarra ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Binding Protein ◽  
Retinol Binding Protein ◽  
Infected People ◽  
Retinol Binding Protein 4 ◽  
Potential Biomarker

scholarly journals The Value of Urinary RBP4 in The Diagnosis of FSGS and other Renal Diseases.

2020 ◽  
Author(s):  
Karolina Marek-Bukowiec ◽  
Andrzej Konieczny ◽  
Krzysztof Ratajczyk ◽  
Katarzyna Macur ◽  
Paulina Czaplewska ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Renal Cell ◽  
Healthy Subjects ◽  
Binding Protein ◽  
Retinol Binding Protein ◽  
Healthy Controls ◽  
Retinol Binding Protein 4

Abstract BackgroundFocal segmental glomerulosclerosis (FSGS) is the leading cause of chronic renal failure worldwide. Unequivocal diagnosis of FSGS can only be made with a renal biopsy, which is an invasive, risk-associated medical procedure. The discovery of non-invasive molecular biomarkers for the diagnosis of FSGS still remains an important scientific goal. This study examines the urinary proteome profile of FSGS patients and reference groups, in order to identify urinary protein expression alterations indicative of FSGS. Methods Urine samples were collected from subjects representing FSGS, IgA nephropathy (IgAN), clear cell renal cell carcinoma (ccRCC), chromophobe renal cell carcinoma (chRCC), and healthy control group, respectively. The samples were pooled and subjected to SWATH-MS proteomics analysis. ELISA was utilized to validate the expression level of Retinol-binding protein 4 (uRBP4) in 130 urine supernatant samples (21 FSGS, 20 IgAN, 31 ccRCC, 21 chRCC, 7 prostate cancer patients and 30 healthy volunteers).ResultsThe MS study identified 194 (FSGS), 179 (IgAN), 271 (ccRCC), 255 (chRCC), and 275 (healthy controls) urinary proteins. The comparative proteomic analysis revealed that Retinol-binding protein 4 clearly discriminates FSGS from the rest of the groups. Increased levels of uRBP4 in FSGS urine specimens were also detected by ELISA (FSGS vs IgAN p=0.0244, FSGS vs ccRCC p=0.004, FSGS vs chRCC p=0.013, FSGS vs prostate cancer p=0.02, FSGS vs healthy controls p<0.00001). Significantly elevated levels of uRBP4 were also observed for IgAN, ccRCC and chRCC versus healthy individuals.ConclusionsUrinary RBP4 protein is significantly upregulated in FSGS in comparison to IgAN, ccRCC, chRCC, prostate cancer patients and healthy subjects. Determining FSGS diagnosis based on uRBP4 expression alone is not possible. Specific uRBP4 concentration cut-off can be applied to accurately distinguish individuals with renal disorder (in general) from healthy subjects. Thus, urinary RBP4 could serve as a screening biomarker identifying people at risk of renal disorders, who should undergo more detailed diagnostics.

scholarly journals Proteomics Analysis for Finding Serum Markers of Ovarian Cancer

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Yushan Cheng ◽  
Chongdong Liu ◽  
Nawei Zhang ◽  
Shengdian Wang ◽  
Zhenyu Zhang
Keyword(s):  
Mass Spectrometry ◽  
Ovarian Cancer ◽  
Cancer Patients ◽  
Plasma Concentrations ◽  
Retinol Binding Protein ◽  
Peptide Ligand ◽  
Healthy Individuals ◽  
Serum Samples ◽  
Potential Biomarker ◽  
Benign Ovarian Tumor

A combination of peptide ligand library beads (PLLB) and 1D gel liquid chromatography-mass spectrometry/mass spectrometry (1DGel-LC-MS/MS) was employed to analyze serum samples from patients with ovarian cancer and from healthy controls. Proteomic analysis identified 1200 serum proteins, among which 57 proteins were upregulated and 10 were downregulated in the sera from cancer patients. Retinol binding protein 4 (RBP4) is highly upregulated in the ovarian cancer serum samples. ELISA was employed to measure plasma concentrations of RBP4 in 80 samples from ovarian cancer patients, healthy individuals, myoma patients, and patients with benign ovarian tumor, respectively. The plasma concentrations of RBP4 ranging from 76.91 to 120.08 ng/mL with the mean value89.13±1.67 ng/mL in ovarian cancer patients are significantly higher than those in healthy individuals (10.85±2.38 ng/mL). Results were further confirmed with immunohistochemistry, demonstrating that RBP4 expression levels in normal ovarian tissue were lower than those in ovarian cancer tissues. Our results suggested that RBP4 is a potential biomarker for diagnostic of screening ovarian cancer.

scholarly journals Plasma retinol-binding protein 4 in the first and second trimester and risk of gestational diabetes mellitus in Chinese women: a nested case-control study

2020 ◽  
Vol 17 (1) ◽  
Author(s):  
Chuyao Jin ◽  
Lizi Lin ◽  
Na Han ◽  
Zhiling Zhao ◽  
Zheng Liu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Binding Protein ◽  
First Trimester ◽  
Retinol Binding Protein ◽  
Second Trimester ◽  
Retinol Binding Protein 4 ◽  
Plasma Retinol

Abstract Background To assess the association between plasma retinol-binding protein 4 (RBP4) levels both in the first trimester and second trimester and risk of gestational diabetes mellitus (GDM). Methods Plasma RBP4 levels and insulin were measured among 135 GDM cases and 135 controls nested within the Peking University Birth Cohort in Tongzhou. Multivariable linear regression analysis was conducted to assess the influence of RBP4 levels on insulin resistance. Conditional logistic regression models were used to compute the odds ratio (OR) and 95% confidence interval (CI) between RBP4 levels and risk of GDM. Results The GDM cases had significantly higher levels of RBP4 in the first trimester than controls (medians: 18.0 μg/L vs 14.4 μg/L; P < 0.05). Plasma RBP4 concentrations in the first and second trimester were associated with fasting insulin, homeostasis model assessment for insulin resistance (HOMA-IR), and the quantitative insulin sensitivity check index (QUICKI) in the second trimester (all P < 0.001). With adjustment for diet, physical activity, and other risk factors for GDM, the risk of GDM increased with every 1-log μg/L increment of RBP4 levels, and the OR (95% CI) was 3.12 (1.08–9.04) for RBP4 in the first trimester and 3.38 (1.03–11.08) for RBP4 in the second trimester. Conclusions Plasma RBP4 levels both in the first trimester and second trimester were dose-dependently associated with increased risk of GDM.

Sign in / Sign up

Export Citation Format

Share Document